Overview

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the use of sugammadex (compared with neostigmine) reduces the rate of postoperative pulmonary complications (PPCs).
Phase:
Phase 4
Details
Lead Sponsor:
Northern Sydney Anaesthesia Research Institute
Collaborators:
Merck Sharp & Dohme Corp.
Northern Sydney and Central Coast Area Health Service
Treatments:
Glycopyrrolate
Neostigmine